Roundhill Russell 2000 0DTE Covered Call Strat ETF vs Summit Therapeutics Inc — how do they compare? Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $26.1 (market cap $159.33M), while Summit Therapeutics Inc trades at $17.35 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 86× Roundhill Russell 2000 0DTE Covered Call Strat ETF's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Roundhill Russell 2000 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill Russell 2000 0DTE Covered Call Strat ETF for 53 Days and Summit Therapeutics Inc for 16 Days on average.
| RDTE | SMMT | |
|---|---|---|
Market Cap | $159.33M | $13.71B |
Volume | 248,058 | 6,173,057 |
Sector | Income / Options Overlay | Health |
52-Week High | $33.66 | $26.38 |
52-Week Low | $25.96 | $12.43 |
Typical Hold Time | 53 Days | 16 Days |
Enterprise Value | — | $13.04B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →